Silverarc Capital Management
Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, ATHA, ITCI, SRRA, VCYT, and represent 40.87% of Silverarc Capital Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$27M), ITCI (+$13M), CTIC (+$11M), SRRA (+$9.0M), VCYT (+$6.8M), APEN (+$6.1M), APLS (+$5.4M), CERS, KRYS, NGM.
- Started 21 new stock positions in GLPG, NGM, APEN, Amylyx Pharmaceuticals, IMUX, VRTX, XBI, BCRX, APLS, ASLN. FMTX, CTIC, PSTX, ELYM, KRYS, CDXS, SNDX, APTX, NBIX, ALGS, ASND.
- Reduced shares in these 10 stocks: ATHA (-$260M), FULC (-$5.2M), RACB, ARVN, AMYT, NXTC, , , Helix Acquisition Corp, ERAS.
- Sold out of its positions in ADGI, Adamas Pharmaceuticals, ARCT, Arena Pharmaceuticals, ARVN, AYLA, CABA, CBIO, CCXI, CRIS.
- Silverarc Capital Management was a net seller of stock by $-190M.
- Silverarc Capital Management has $242M in assets under management (AUM), dropping by 36.62%.
- Central Index Key (CIK): 0001816307
Tip: Access up to 7 years of quarterly data
Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Silverarc Capital Management
Companies in the Silverarc Capital Management portfolio as of the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Call Option (XBI) | 11.2 | $27M | NEW | 300k | 89.88 | |
| Athira Pharma (ATHA) | 11.2 | $27M | -90% | 10k | 2696.40 | |
| Intra Cellular Therapies (ITCI) | 7.8 | $19M | +203% | 309k | 61.19 | |
| Sierra Oncology Com New (SRRA) | 5.9 | $14M | +171% | 443k | 32.05 | |
| Veracyte (VCYT) | 4.9 | $12M | +137% | 426k | 27.57 | |
| Cti Biopharma (CTIC) | 4.3 | $11M | NEW | 2.3M | 4.67 | |
| Merus N V (MRUS) | 3.6 | $8.6M | -6% | 325k | 26.44 | |
| Cerus Corporation (CERS) | 3.2 | $7.7M | +125% | 1.4M | 5.49 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 2.9 | $7.1M | +28% | 67k | 105.22 | |
| Apollo Endosurgery (APEN) | 2.5 | $6.1M | NEW | 1.0M | 6.05 | |
| Apellis Pharmaceuticals (APLS) | 2.2 | $5.4M | NEW | 105k | 50.81 | |
| Aclaris Therapeutics (ACRS) | 2.0 | $4.7M | +58% | 275k | 17.24 | |
| ImmunoGen Call Option (IMGN) | 1.9 | $4.5M | +45% | 945k | 4.76 | |
| Iteos Therapeutics (ITOS) | 1.8 | $4.5M | +18% | 139k | 32.18 | |
Setup an alertSilverarc Capital Management will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Biohaven Pharmaceutical Holding (BHVN) | 1.8 | $4.4M | +65% | 103k | 42.53 | |
| Cogent Biosciences (COGT) | 1.8 | $4.3M | -15% | 574k | 7.49 | |
| Mirati Therapeutics (MRTX) | 1.6 | $3.8M | 46k | 82.22 | ||
| Immatics SHS (IMTX) | 1.5 | $3.6M | 445k | 7.99 | ||
| Krystal Biotech (KRYS) | 1.3 | $3.1M | NEW | 47k | 66.53 | |
| Ngm Biopharmaceuticals (NGM) | 1.3 | $3.1M | NEW | 201k | 15.25 | |
| Otonomy (OTIC) | 1.2 | $2.9M | +18% | 1.2M | 2.40 | |
| Morphic Hldg (MORF) | 1.1 | $2.8M | +19% | 69k | 40.15 | |
| United Therapeutics Corporation (UTHR) | 1.1 | $2.7M | -29% | 15k | 179.43 | |
| Galapagos Nv Spon Adr (GLPG) | 1.1 | $2.5M | NEW | 41k | 62.02 | |
| Crinetics Pharmaceuticals In (CRNX) | 1.0 | $2.5M | +130% | 114k | 21.95 | |
| Insmed Com Par $.01 (INSM) | 1.0 | $2.4M | -41% | 102k | 23.50 | |
| Miragen Therapeutics (VRDN) | 1.0 | $2.3M | +18% | 126k | 18.49 | |
| Seres Therapeutics (MCRB) | 1.0 | $2.3M | +18% | 327k | 7.12 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.9 | $2.3M | +43% | 186k | 12.15 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 0.8 | $2.0M | NEW | 7.6k | 260.93 | |
| Neurocrine Biosciences (NBIX) | 0.8 | $1.9M | NEW | 21k | 93.74 | |
| Leap Therapeutics (LPTX) | 0.7 | $1.8M | +66% | 1.0M | 1.75 | |
| Syndax Pharmaceuticals (SNDX) | 0.7 | $1.8M | NEW | 101k | 17.38 | |
| Viewray (VRAY) | 0.7 | $1.7M | +135% | 436k | 3.92 | |
| Jounce Therapeutics (JNCE) | 0.7 | $1.7M | +19% | 248k | 6.79 | |
| Codexis (CDXS) | 0.7 | $1.7M | NEW | 81k | 20.62 | |
| Point Biopharma Global (PNT) | 0.7 | $1.6M | +185% | 205k | 7.97 | |
| Forma Therapeutics Hldgs SHS (FMTX) | 0.7 | $1.6M | NEW | 175k | 9.30 | |
| Iveric Bio Put Option (ISEE) | 0.7 | $1.6M | +215% | 95k | 16.83 | |
| Aslan Pharmaceuticals Ads (ASLN) | 0.7 | $1.6M | NEW | 500k | 3.18 | |
| Seagen (SGEN) | 0.7 | $1.6M | -6% | 11k | 144.03 | |
| Xenon Pharmaceuticals (XENE) | 0.6 | $1.4M | +420% | 101k | 14.13 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.6 | $1.4M | NEW | 25k | 57.12 | |
| Cyclacel Pharmaceuticals (CYCC) | 0.6 | $1.4M | +19% | 463k | 3.05 | |
| Stereotaxis Com New (STXS) | 0.5 | $1.3M | +18% | 346k | 3.73 | |
| Medicus Sciences Acquisition Cl A Shs (MSAC) | 0.5 | $1.3M | +19% | 131k | 9.78 | |
| Amryt Pharma Sponsored Ads (AMYT) | 0.5 | $1.3M | -70% | 153k | 8.27 | |
| Polypid SHS (PYPD) | 0.5 | $1.2M | +19% | 218k | 5.46 | |
| Lucira Health (LHDX) | 0.5 | $1.1M | +40% | 311k | 3.57 | |
| Eloxx Pharmaceuticals (ELOX) | 0.5 | $1.1M | +54% | 2.0M | 0.56 | |
| Poseida Therapeutics I (PSTX) | 0.4 | $1.1M | NEW | 240k | 4.48 | |
| Nextcure (NXTC) | 0.4 | $953k | -72% | 196k | 4.86 | |
| Compugen Ord (CGEN) | 0.4 | $865k | -40% | 269k | 3.22 | |
| Immunic (IMUX) | 0.3 | $774k | NEW | 69k | 11.30 | |
| Eliem Therapeutics (ELYM) | 0.3 | $741k | NEW | 88k | 8.39 | |
| Aptinyx Put Option (APTX) | 0.2 | $458k | NEW | 202k | 2.27 | |
| Amylyx Pharmaceuticals | 0.2 | $386k | NEW | 30k | 12.87 | |
| Evogene SHS (EVGN) | 0.2 | $384k | +19% | 296k | 1.30 | |
| Mereo Biopharma Group Ads (MREO) | 0.1 | $264k | -35% | 236k | 1.12 | |
| Celldex Therapeutics Com New (CLDX) | 0.1 | $256k | +19% | 46k | 5.62 | |
| Biogen Idec (BIIB) | 0.1 | $230k | +133% | 10k | 22.44 | |
| BioCryst Pharmaceuticals (BCRX) | 0.1 | $197k | NEW | 102k | 1.92 | |
| Bellus Health Com New (BLU) | 0.1 | $177k | +238% | 1.2M | 0.14 | |
| Calithera Biosciences (CALA) | 0.0 | $74k | +19% | 222k | 0.33 | |
| Benitec Biopharma (BNTC) | 0.0 | $57k | 493k | 0.12 | ||
| Renovacor *w Exp 99/99/999 (RCOR.WS) | 0.0 | $33k | 105k | 0.31 | ||
| Aligos Therapeutics (ALGS) | 0.0 | $23k | NEW | 11k | 2.16 | |
| Medicus Sciences Acquisition *w Exp 02/12/202 (MSACW) | 0.0 | $21k | 50k | 0.42 | ||
Past Filings by Silverarc Capital Management
SEC 13F filings are viewable for Silverarc Capital Management going back to 2020
- Silverarc Capital Management 2022 Q1 filed May 13, 2022
- Silverarc Capital Management 2021 Q3 filed Nov. 15, 2021
- Silverarc Capital Management 2021 Q2 filed Aug. 16, 2021
- Silverarc Capital Management 2021 Q1 filed May 18, 2021
- Silverarc Capital Management 2020 Q4 filed Feb. 16, 2021